期刊文献+

胃肠道间质瘤分子靶向治疗继发性耐药基因突变的研究 被引量:1

Gastrointestinal stromal tumor molecular targeted treatment for secondary resistance mutations
下载PDF
导出
摘要 目的探讨胃肠道间质瘤(GIST)患者酪氨酸激酶受体(KIT)和血小板源性生长受体(PDGFRA)基因突变的特点,以及伊马替尼的继发耐药机制。方法对98例GIST患者肿瘤组织进行DNA抽提、聚合酶链反应(PCR)扩增和直接测序,检测KIT基因外显子9、11、13、17和PDGFRA基因12、18外显子突变;并对伊马替尼继发耐药的65例患者进行2次检测。结果 98例患者中,KIT突变79例(80.6%),其中外显子11突变61例(62.2%),外显子9突变18例(18.4%);PDGFRA突变3例(3.1%)。不同性别、年龄以及晚期GIST患者和潜在恶性的GIST患者间突变比较差异无统计学意义(P>0.05);而不同部位GIST的KIT外显子11突变发生率差异有统计学意义(P<0.05)。65例继发耐药病例中,4例患者发生二次突变,表现为KIT基因第17外显子密码子第2467位点的T为G所替换(T2467G),导致823密码子编码氨基酸由酪氨酸转变为天冬氨酸。结论 KIT基因突变在GIST患者中常见,不同部位间KIT外显子11突变发生率差异有统计学意义。伊马替尼继发耐药可能与KIT基因第17外显子密码子第2467位点T为G所替换(T2467G)相关。 Objective To investiate the gastrointestinal stromal tumor(GIST)patients with tyrosine kinase receptor(KIT)and platelet-derived growth factor receptor(PDGFRA)gene mutation characteristics,as well as secondary imatinib resistance mechanisms.Methods 98 cases of patients with GIST tumor were examed with tissue for DNA extraction,polymerase chain reaction(PCR)amplification and direct sequencing to detect KIT exon 9,11,13,17 and PDGFRA gene mutation in exon 12,18;and secondary second test were performed in 65 imatinib-resistant patients.Results In the 98 patients,KIT mutations were found in 79 cases(80.6%),of which exon 11 mutations in 61 cases(62.2%),exon 9 mutations in 18 cases(18.4%);PDGFRA mutations in 3 cases(3.1%).Gender,age,and among patients with advanced GIST GIST patients and potentially malignant mutation was with no significant difference(P 0.05);while different parts of GIST KIT exon 11mutation incidence was significantly(P0.05).In 65 cases of secondary resistant cases,four patients developed a secondary mutation,gene expression of KIT exon 17 codon 2467 point T is replaced by G(T2467G),resulting in 823 amino acids encoded by the codons casein converted to aspartic acid.Conclusion It demonstrated that the KIT mutations are common in GIST patients,between different parts of the KIT exon 11 mutation rate difference was statistically significant.Secondary imatinib resistance may be associated with KIT exon 17 of the gene codon 2467 point T is replaced by G(T2467G)related.
出处 《疑难病杂志》 CAS 2014年第2期169-171,174,共4页 Chinese Journal of Difficult and Complicated Cases
关键词 胃肠道间质瘤 伊马替尼 基因突变 耐药性 Gastrointestinal stromal tumor Imatinib Gene mutation Drug resistance
  • 相关文献

参考文献11

  • 1Ronald P DeMatteo,Karla V Ballman,Cristina R Antonescu,Robert G Maki,Peter WT Pisters,George D Demetri,Martin E Blackstein,Charles D Blanke,Margaret von Mehren,Murray F Brennan,Shreyaskumar Patel,Martin D McCarter,Jonathan A Polikoff,Benjamin R Tan,Kouros Owzar.Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial[J].The Lancet.2009(9669)
  • 2李金鹏,宋金龙.甲磺酸伊马替尼联合肝动脉化疗栓塞术治疗胃肠间质瘤肝转移的疗效观察[J].疑难病杂志,2012,11(6):430-432. 被引量:10
  • 3Yamanaka Takeharu,Matsumoto Shigemi,Teramukai Satoshi,Ishiwata Ryota,Nagai Yoji,Fukushima Masanori.The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer[].Oncology.2008
  • 4祝燕军,钱立勇,黄燕凤.DOG1蛋白在胃肠道间质瘤诊断中的价值研究[J].中国全科医学,2012,15(26):3025-3027. 被引量:2
  • 5Balachandran Vinod P,Cavnar Michael J,Zeng Shan,Bamboat Zubin M,Ocuin Lee M,Obaid Hebroon,Sorenson Eric C,Popow Rachel,Ariyan Charlotte,Rossi Ferdinand,Besmer Peter,Guo Tianhua,Antonescu Cristina R,Taguchi Takahiro,Yuan Jianda,Wolchok Jedd.Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido[].Nature Medicine.2011
  • 6Souto Juan Carlos,Vila Luis,Brú Antonio.Polymorphonuclear neutrophils and cancer: intense and sustained neutrophilia as a treatment against solid tumors[].Medicinal Research Reviews.2009
  • 7Heikki Joensuu,Ronald P. DeMatteo.The Management of Gastrointestinal Stromal Tumors: A Model for Targeted and Multidisciplinary Therapy of Malignancy[].ANNUAL REVIEW OF MEDICINE;Annual Review of Medicine.2012
  • 8王春萌,师英强,董锐增,傅红,赵广法,杜春燕,周烨,周晓燕.伊马替尼耐药胃肠间质瘤的免疫组织化学和基因特征[J].肿瘤,2008,28(12):1064-1068. 被引量:6
  • 9Nicolas F Delahaye,Sylvie Rusakiewicz,Isabelle Martins,Cédric Ménard,Stephan Roux,Luc Lyonnet,Pascale Paul,Matthieu Sarabi,Nathalie Chaput,Michaela Semeraro,Véronique Minard-Colin,Vichnou Poirier-Colame,Kariman Chaba,Caroline Flament,Vér.Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors[].Nature Medicine.2011
  • 10Martine Van Glabbeke.Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients[].Journal of Clinical Oncology.2010

二级参考文献32

  • 1I-ShyanSheen,Kuo-ShyangJeng,Shou-ChuanShih,Chih-RoaKao,Wen-HsingChang,Horng-YuanWang,Po-ChuanWang,Tsang-EnWang,Li-RungShyung,Chih-ZenChen.Clinical significance of the expression of isoform 165 vascular endothelial growth factor mRNA in noncancerous liver remnants of patients with hepatocellular carcinoma[J].World Journal of Gastroenterology,2005,11(2):187-192. 被引量:41
  • 2VERWEIJ J, CASALI PG, ZALCBERG J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial [ J ]. Lancet, 2004, 364 ( 9440 ) : 1127- 1134.
  • 3VAN GLABBEKE M, VERWEU J, CASALI PG, et aL Initial and late resistance to imatinib in advanced gastro-intestinal stromal tumors are predicted by different prognostic factors: a European Organization for Research and Treatment of Cancer-ltalian Sarcoma Group-Australasian Gastrointestinal Trials Group Study[ J]. J Clin Oncol, 2005 23(24) :5795-804.
  • 4FLETCHER J A, CORLESS C L, DIMITRIJEVIC S, et al. Mechanisms of resistance to imatinib mesylate in advanced gastrointestinal stromal[C]. Proc Am Soc Clin Oncol, 2003, 22: 815.
  • 5THERASSE P, ARBUCK S G, EISENHAUER E A, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada[J]. J Natl Cancer lnst, 2000, 92(3) :205-216.
  • 6PAULS K, MERKELBACH-BRUSE S, THAL D, et al. PDGFR-α and c-kit mutated gastrointestinal stromal tumors (GISTs) are characterized by distinctive histological and immunohistochemical features[ J]. Histopathology, 2005, 46 (2) : 166-175.
  • 7WARDELMANN E, LOSEN I, HANS V, et al. Deletion of Trp- 557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors [ J ]. lnt J Cancer, 2003, 106 (6) :887-895.
  • 8WARDELMANN E, HRYCHYK A, MERKELBACH-BRUSE S, o et al. Association of platelet-derived growth factor receptor a mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors [ J ]. J Mol Diagn, 2004, 6(3) :197-204.
  • 9KIKUCHI H, YAMASHITA K, KAWABATA T, et al. Immunohistochemical and genetic features of gastric and metastatic liver gastrointestinal stromal tumors : Sequential analyses [ J ]. Cancer Sci, 2006, 97(2) :127-132.
  • 10WARDELMANN E,MERKELBACH-BRUSE S,PAULS K,et al. Polyclonal evolution of multiple secondary K/T mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate [J]. Clin Cancer Res, 2006, 12(6) :1743-1749.

共引文献17

同被引文献3

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部